NASDAQ:STOK Stoke Therapeutics (STOK) Stock Price, News & Analysis $11.55 -0.10 (-0.86%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$11.64 +0.09 (+0.78%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Stoke Therapeutics Stock (NASDAQ:STOK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Stoke Therapeutics alerts:Sign Up Key Stats Today's Range$11.32▼$11.8650-Day Range$8.66▼$11.8452-Week Range$5.35▼$16.15Volume403,403 shsAverage Volume670,362 shsMarket Capitalization$630.63 millionP/E Ratio14.62Dividend YieldN/APrice Target$23.20Consensus RatingBuy Company Overview Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Read More Stoke Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreSTOK MarketRank™: Stoke Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 225th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingStoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageStoke Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Stoke Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.01) to ($2.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stoke Therapeutics is 14.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.22.Price to Earnings Ratio vs. SectorThe P/E ratio of Stoke Therapeutics is 14.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.17.Price to Book Value per Share RatioStoke Therapeutics has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Stoke Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.51% of the float of Stoke Therapeutics has been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.Change versus previous monthShort interest in Stoke Therapeutics has recently increased by 0.67%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStoke Therapeutics does not currently pay a dividend.Dividend GrowthStoke Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.59 Percentage of Shares Shorted24.51% of the float of Stoke Therapeutics has been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.Change versus previous monthShort interest in Stoke Therapeutics has recently increased by 0.67%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment0.31 News SentimentStoke Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Stoke Therapeutics this week, compared to 5 articles on an average week.Search Interest2 people have searched for STOK on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $82,354.00 in company stock.Percentage Held by InsidersOnly 9.50% of the stock of Stoke Therapeutics is held by insiders.Read more about Stoke Therapeutics' insider trading history. Receive STOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address STOK Stock News HeadlinesStoke Therapeutics, Inc. (NASDAQ:STOK) Insider Barry Ticho Sells 1,745 SharesJune 5, 2025 | insidertrades.comPorch pirates target Stoke-on-Trent as parcels swiped from doorsteps3 hours ago | uk.news.yahoo.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. July 3 at 2:00 AM | Porter & Company (Ad)Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $23.20 Average Target Price from BrokeragesJuly 3 at 2:41 AM | americanbankingnews.comStoke City on brink of agreement for Plymouth Argyle record signingJuly 2 at 8:32 PM | msn.comStockley named Stoke's new academy managerJuly 2 at 8:32 PM | msn.comSTOK Stoke Therapeutics, Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comAnalysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Legend Biotech (LEGN)June 28, 2025 | theglobeandmail.comSee More Headlines STOK Stock Analysis - Frequently Asked Questions How have STOK shares performed this year? Stoke Therapeutics' stock was trading at $11.03 at the beginning of 2025. Since then, STOK stock has increased by 4.7% and is now trading at $11.55. View the best growth stocks for 2025 here. How were Stoke Therapeutics' earnings last quarter? Stoke Therapeutics, Inc. (NASDAQ:STOK) announced its quarterly earnings results on Monday, March, 24th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. The firm had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a net margin of 26.33% and a trailing twelve-month return on equity of 19.08%. When did Stoke Therapeutics IPO? Stoke Therapeutics (STOK) raised $100 million in an IPO on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager. How do I buy shares of Stoke Therapeutics? Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Stoke Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stoke Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA). Company Calendar Last Earnings3/24/2025Today7/02/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:STOK CIK1623526 Webwww.stoketherapeutics.com Phone(781) 430-8200FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$23.20 High Stock Price Target$35.00 Low Stock Price Target$17.00 Potential Upside/Downside+100.9%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$0.79 Trailing P/E Ratio14.62 Forward P/E RatioN/A P/E GrowthN/ANet Income-$88.98 million Net Margins26.33% Pretax Margin27.00% Return on Equity19.08% Return on Assets15.72% Debt Debt-to-Equity RatioN/A Current Ratio8.41 Quick Ratio8.41 Sales & Book Value Annual Sales$36.56 million Price / Sales17.25 Cash FlowN/A Price / Cash FlowN/A Book Value$4.32 per share Price / Book2.67Miscellaneous Outstanding Shares54,600,000Free Float49,410,000Market Cap$630.63 million OptionableOptionable Beta1.14 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:STOK) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.